Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes: A Systematic Review and Network Meta-analysis
The DOI matches its Crossref record, with a small difference in title or year; 34 of the 34 references it cites were found in a registry or an index.
Abstract
Background: Several pharmacologic options for type 2 diabetes are available. Purpose: To compare benefits and harms of glucose-lowering drugs in adults with type 2 diabetes. Data Sources: Several databases from inception through 18 December 2019 and ClinicalTrials.gov on 10 April 2020. Study Selection: English-language randomized trials that had at least 24 weeks of intervention and assessed the effects of glucose-lowering drugs on mortality, glycemic, and vascular outcomes. Data Extraction: Pairs of reviewers extracted data and appraised risk of bias. Data Synthesis: 453 trials assessing 21 antidiabetic interventions from 9 drug classes were included. Interventions included monotherapies (134 trials), add-on to metformin-based therapies (296 trials), and monotherapies versus add-on to metformin therapies (23 trials). There were no differences between treatments in drug-naive patients at low cardiovascular risk. Insulin regimens and specific glucagon-like peptide-1 receptor agonists (GLP-1 RAs) added to metformin-based background therapy produced the greatest reductions in hemoglobin A1c level. In patients at low cardiovascular risk receiving metformin-based background treatment (298 trials), there were no clinically meaningful differences between treatments for mortality and vascular outcomes. In patients at increased cardiovascular risk receiving metformin-based background treatment (21 trials), oral semaglutide, empagliflozin, liraglutide, extended-release exenatide, and dapagliflozin reduced all-cause mortality. Oral semaglutide, empagliflozin, and liraglutide also reduced cardiovascular death. Odds of stroke were lower with subcutaneous semaglutide and dulaglutide. Sodium–glucose cotransporter-2 (SGLT-2) inhibitors reduced heart failure hospitalization and end-stage renal disease. Subcutaneous semaglutide and canagliflozin increased diabetic retinopathy and amputation, respectively. Limitation: Inconsistent definitions of cardiovascular risk and low-level confidence in some estimates for patients at low cardiovascular risk. Conclusion: In diabetic patients at low cardiovascular risk, no treatment differs from placebo for vascular outcomes. In patients at increased cardiovascular risk receiving metformin-based background therapy, specific GLP-1 RAs and SGLT-2 inhibitors have a favorable effect on certain cardiovascular outcomes. Primary Funding Source: European Foundation for the Study of Diabetes, supported by an unrestricted educational grant from AstraZeneca. (PROSPERO: CRD42019122043)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In a network meta-analysis of 453 trials assessing glucose-lowering medications from nine drug classes, the greatest reductions in HbA1c were seen with insulin regimens and GLP-1 RA (223).”
In the citing paper
“However, the comparative effectiveness of the two drug classes has been assessed in three recent network meta-analyses, which found that, in people with type 2 diabetes, SGLT2i were superior to GLP-1 RA in reducing HHF and a composite kidney outcome, while GLP-1 RA seemed more ef fi cacious in reducing the risk of stroke (223,259,260).”
In the citing paper
“Some inferences about the effect of glucose-lowering medications as primary cardiovascular prevention in populations with low cardiovascular risk can be made from network meta-analyses, suggesting that no agent or drug class has a notable bene fi cial effect on cardiovascular events in lowrisk individuals with diabetes (223,259).”
In the citing paper
“In a large systemic review and network analysis, including several GLP-1RAs, subcutaneous semaglutide was the only glucose-lowering drug for which this signal was observed”
From Safety of Semaglutide (2021) · cites this paper as [120]
In the citing paper
“A systematic review and meta-analysis of CGM use in adults with type 2 diabetes (12 randomized clinical trials with 1248 participants taking insulin, GLP-1RA, or oral glucose-lowering medications) reported that CGM led to a mean difference in HbA1C reduction over 10 to 34 weeks of −0.31% (95% CI, −0.43% to −0.19%) compared with BGM.49”
From Diagnosis and Treatment of Type 2 Diabetes in Adults: A Review (2025) · cites this paper as [49]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
RoB 2: a revised tool for assessing risk of bias in randomised trials
Sterne, J. A. C., Savović, J., Page, M. J., Elbers, R. G., Blencowe, N. S., Boutron, I., Cates, C. J., Cheng, H.-Y., Corbett, M. S., Eldridge, S. M., et al. (2019) · BMJ · doi:10.1136/bmj.l4898 · Cited by 34,787
Hutton, B., Salanti, G., Caldwell, D. M., Chaimani, A., Schmid, C. H., Cameron, C., Ioannidis, J. P. A., Straus, S., Thorlund, K., Jansen, J. P., et al. (2015) · Annals of Internal Medicine · doi:10.7326/m14-2385 · Cited by 8,269 · cited 1×
“ods (9), and report detailed methods in section 1 of the Supplement (available at Annals.”
MethodDapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Cosentino, F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V., Federici, M., Filippatos, G., Grobbee, D. E., Hansen, T. B., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz486 · Cited by 4,763
Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riesmeyer, J. S., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31149-3 · Cited by 3,163
Zelniker, T. A., Wiviott, S. D., Raz, I., Im, K., Goodrich, E. L., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Furtado, R. H. M., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32590-x · Cited by 2,845 · cited 1×
“On the basis of pairwise meta-analyses of cardiovascular outcome trials, compared with placebo, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) reduce cardiovascular death and stroke (4), whereas sodium–glucose cotransporter-2 (SGLT-2) inhibitors reduce heart failure hospitalization (5) and end-stage renal disea…”
BackgroundChecking consistency in mixed treatment comparison meta-analysis
Dias, S., Welton, N. J., Caldwell, D. M., & Ades, A. E. (2010) · Statistics in Medicine · doi:10.1002/sim.3767 · Cited by 2,521 · cited 1×
“We evaluated consistency in the networks both locally by comparing direct with indirect evidence (19) and globally by using the design-by-treatment interaction model (20).”
MethodConsistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies
Higgins, J. P. T., Jackson, D., Barrett, J. K., Lu, G., Ades, A. E., & White, I. R. (2012) · Research Synthesis Methods · doi:10.1002/jrsm.1044 · Cited by 2,098 · cited 1×
“We evaluated consistency in the networks both locally by comparing direct with indirect evidence (19) and globally by using the design-by-treatment interaction model (20).”
MethodOral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Husain, M., Birkenfeld, A. L., Donsmark, M., Dungan, K., Eliaschewitz, F. G., Franco, D. R., Jeppesen, O. K., Lingvay, I., Mosenzon, O., Pedersen, S. D., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1901118 · Cited by 1,997
CINeMA: an approach for assessing confidence in the results of a network meta-analysis
Nikolakopoulou, A., Higgins, J. P. T., Papakonstantinou, T., Chaimani, A., Del Giovane, C., Egger, M., & Salanti, G. (2020) · PLOS Medicine · doi:10.1371/journal.pmed.1003082 · Cited by 1,935
Research works printed but not linked: 1
- Schwarzer G, 2007, R news, 7, 40
Cited by
Items 201–300 of 401
Xu, Y., Wang, X., She, Y., Liu, J., & Zhang, Q. (2024) · Endocrine Journal · doi:10.1507/endocrj.ej24-0168 · Cited by 6
Effectiveness of Consumer Dispute Resolution through the Consumer Dispute Resolution Agency (BPSK)
Yuwono, M. S., & Santiago, F. (2024) · Journal of Multidisciplinary Sustainability Asean. · doi:10.70177/ijmsa.v1i6.1827 · Cited by 6
Hammerman, A., Moore, C. M., Aboalhasan, E., Azuri, J., & Arbel, R. (2022) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2022.01.027 · Cited by 6
Bartels, E. C. M., den Braver, N. R., den Berg, K. J. B., Rutters, F., van der Heijden, A. A. W. A., & Beulens, J. W. J. (2022) · European Journal of Nutrition · doi:10.1007/s00394-022-02847-6 · Cited by 6
Avgerinos, I., Kakotrichi, P., Karagiannis, T., Bekiari, E., & Τσάπας, Α. (2024) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2024.2324918 · Cited by 7
Self-citationKroopnick, J. M., & Davis, S. N. (2022) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2089021 · Cited by 6
Dai, J.-W., Lin, Y., Li, X., Tseng, C.-J., Tsai, M., Yang, N., Hung, M., & Chen, T. (2024) · Scientific Reports · doi:10.1038/s41598-024-79255-9 · Cited by 5
Xie, Z., Gan, B., Cao, W., Liu, J., & Chen, J. (2025) · Obesity · doi:10.1002/oby.70065 · Cited by 5
Lehenbauer, K. S., Nelson, A. J., Nodari, S., Sverdlov, A. L., & Harrington, J. (2025) · Heart Failure Reviews · doi:10.1007/s10741-025-10579-y · Cited by 5
Malandris, K., Papandreou, S., Vasilakou, D., Kakotrichi, P., Sarakapina, A., Kalopitas, G., Karagiannis, T., Γιουλεμέ, Ό., Bekiari, E., Liakos, A., et al. (2024) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.16559 · Cited by 5
Self-citationCosts of treating type 2 diabetes mellitus and its complications
Petrović, N. Z., Milosavljević, M. N., Gojak, R., Đešević, M., Lakić, D., Stević, I., & Јаnkovic, S. (2024) · Biotechnology & Biotechnological Equipment · doi:10.1080/13102818.2024.2399941 · Cited by 5
Glucose-Lowering and Metabolic Effects of SGLT2 Inhibitors
Mordi, I. R., & Lang, C. C. (2022) · Heart Failure Clinics · doi:10.1016/j.hfc.2022.03.004 · Cited by 5
Wehrman, G., Halton, M., Riveland, B., Potter, E. M., & Gaddy, M. A. (2022) · Journal of Pharmacy Practice · doi:10.1177/08971900221134174 · Cited by 5
Park, S., Jeong, H. E., Bea, S., Yu, O. H. Y., Cho, Y. M., You, S. C., Man, K. K. C., & Shin, J. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15221 · Cited by 5
The benefits of hypoglycemic therapy for patients with obstructive sleep apnea
Lin, R., Yan, W., He, M., Liu, B., Su, X., Yi, M., & Zhang, Y. (2024) · Sleep And Breathing · doi:10.1007/s11325-024-03015-2 · Cited by 5
Siafarikas, C., Karamanakos, G., Makrilakis, K., Tsolakidis, A., Mathioudakis, K., & Liatis, S. (2024) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-2307-4631 · Cited by 5
Parsiani, R., Grace, T., Green, C. R., Castle, J. R., & Wilson, L. M. (2025) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_773_24 · Cited by 5
Flores, B. A., León-Vázquez, M. D. L. L., & Juárez, A. B. (2023) · PubMed Central · doi:10.5281/zenodo.8200441 · Cited by 6
Muller, N., Busch, M., Gerdes, C., & Wolf, G. (2023) · Nephrologie aktuell · doi:10.1055/a-2055-3322 · Cited by 5
Liu, Y., Ma, J., Guo, J., Lü, H., Zhang, Y., & Chen, Y. (2021) · International Journal of General Medicine · doi:10.2147/ijgm.s340642 · Cited by 5
Shi, Y., Zhang, J., Xin, X., Liu, L., Wu, Y., Cheng, Y., Zhang, L., Su, H., & Zhao, Y. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01886-3 · Cited by 4
Zhu, Y., Zhang, W., Qu, H.-L., Zhang, Y., Zhou, R.-Q., Li, P., Wang, F., Zhang, Y., Liu, H., Li, S., et al. (2025) · World Journal of Diabetes · doi:10.4239/wjd.v16.i12.112423 · Cited by 4
Bu, F., Wu, R., Ostropolets, A., Aminorroaya, A., Chen, H. Y., Chai, Y., Dhingra, L. S., Falconer, T., Hsu, J. C., Kim, C., et al. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2026.02.5123 · Cited by 4
Tentolouris, A., Filippatos, C., Tepetes, N.-I., Gavriatopoulou, M., Terpos, E., Briasoulis, Α., Stamatelopoulos, K. S., & Filippatos, T. D. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70841 · Cited by 4
XBP1-mediated transcriptional regulation of SLC5A1 in human epithelial cells in disease conditions
Sun, Y., Zhang, Y., Zhang, J., Chen, Y. E., Jin, J., Zhang, K., Mou, H., Liang, X., & Xu, J. (2024) · Cell & Bioscience · doi:10.1186/s13578-024-01203-x · Cited by 4
Xie, Z., Hu, J., Li, M., Hu, X. X., & Chen, J. (2024) · Risk Management and Healthcare Policy · doi:10.2147/rmhp.s455897 · Cited by 4
Yoon, J., Lee, D., Song, H. J., Hong, D., Park, J. S., Hong, C.-H., An, K. M., Lee, J. W., Park, J.-T., Yoon, H., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117044 · Cited by 4
Hau, K. T., Mohamed, M., & Leong, X.-B. (2024) · Journal of Diabetology · doi:10.4103/jod.jod_80_24 · Cited by 4
Wu, X., He, J., Wu, J., Liu, W., Xu, Y., Li, Y., Zhang, J., & Wang, Q. (2025) · Clinical Pharmacokinetics · doi:10.1007/s40262-025-01541-0 · Cited by 4
A data-driven approach to improve wellness and reduce recurrence in cancer survivors
Hariharan, R., Hood, L., & Price, N. D. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1397008 · Cited by 4
Efficacy of iGlarLixi on 5-year risk of diabetes-related complications: A simulation study
Shao, H., Kianmehr, H., Guo, J. S., Li, P., Fonseca, V. A., & Shi, L. (2022) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2022.108132 · Cited by 4
Chen, H., Meng, R., Yang, Y., & Yu, T.-H. (2023) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2023.2182290 · Cited by 4
Pharmacotherapy of Obesity and Metabolic Syndrome
Duan, D., & Ahima, R. S. (2023) · Springer eBooks · doi:10.1007/978-3-031-40116-9_44 · Cited by 4
Hur, K. Y. (2021) · Journal of Korean Diabetes · doi:10.4093/jkd.2021.22.4.250 · Cited by 4
Nomoto, H., Furusawa, S., Nakamura, A., Takeuchi, J., Nagai, S., Yokoyama, H., Sakuma, I., Taneda, S., Kurihara, Y., Aoki, S., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-056885 · Cited by 4
Ribero, V. A., Alwan, H., Efthimiou, O., Abolhassani, N., Bauer, D. C., Henrard, S., Christiaens, A., Waeber, G., Rodondi, N., Gencer, B., et al. (2023) · medRxiv · doi:10.1101/2023.03.13.23287105 · Cited by 4
Otten, J., Tellström, A., Schien, C., Chninou, Y., Lindholm, L. H., Winkvist, A., Liv, P., & Stomby, A. (2025) · BMJ Open · doi:10.1136/bmjopen-2024-095100 · Cited by 3
He, Y., Zeng, C., Zhang, Y., Wu, Q., Xiao-yu, Z., Yan, P., Xu, Y., Guo, M., & Teng, F. (2025) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.70097 · Cited by 3
Fériz, K., Rincón, A. R., Tovar, H., Restrepo-Erazo, K., Yepes, C. A., Brito, E. M., Gómez, N. B., Amézquita, Y. C. H., Iriarte-Durán, M. B., Jimenez, L., et al. (2025) · Revista Colombiana de Endocrinología Diabetes & Metabolismo · doi:10.53853/encr.12.3.907 · Cited by 3
Zhang, X., Mao, S., Chen, X., Yang, M., Duan, J., Kennedy, J. F., & Xiao, P. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.149623 · Cited by 3
Chen, C., Li, X., Yan, H., Liu, J., Cao, Y., Zhao, H., Liu, S., Wang, Y., Sun, Y., Jia, B., et al. (2025) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2025.104488 · Cited by 3
Zbârcea, C. E., Marineci, C., Valeanu, A., Chiriţă, C., & Șeremet, O. C. (2026) · Diabetology · doi:10.3390/diabetology7060108 · Cited by 3
Rangwala, H. S., Fatima, H., Ali, M., Mustafa, M. S., Shafique, M. A., Rangwala, B. S., & Abbas, S. R. (2024) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-024-01412-8 · Cited by 3
Lu, D., Zheng, R., Li, A., & Zhang, J. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v16.i2.98552 · Cited by 3
Gagnon, C. A., Buchanan, K., Deaver, J. M., Schmitt, J. A., Lahart, I. M., Shetty, S., Ashraf, A. P., & Pappachan, J. M. (2025) · World Journal of Diabetes · doi:10.4239/wjd.v16.i7.106890 · Cited by 3
Mohamed, A. S., Ahmad, H. M., Sharawy, M. A., & Kamel, F. (2024) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-024-00818-7 · Cited by 3
Khan, H. U., Akhtar, B., Singla, B., Mughal, H. M. F., Hamid, A., Khan, Z. U., Ismail, S., Sana, M., & Khaliq, M. (2025) · Cureus · doi:10.7759/cureus.84137 · Cited by 3
Amin, S., & Putri, A. C. (2025) · Journal of Innovative and Creativity (Joecy) · doi:10.31004/joecy.v5i3.171 · Cited by 3
Payment, Coverage, and Health Economics of SGLT2 Inhibitors
Pham, N.-Y. T., Argyropoulos, C., & Koppula, S. (2021) · Kidney360 · doi:10.34067/kid.0000742021 · Cited by 3
Echouffo-Tcheugui, J. B., Turchin, A., Rosenson, R. S., Fonarow, G. C., Goyal, A., de Lemos, J. A., & Arnold, S. V. (2022) · The American Journal of Medicine · doi:10.1016/j.amjmed.2022.06.016 · Cited by 3
Lee, C. G., & Cefalu, W. T. (2020) · Annals of Internal Medicine · doi:10.7326/m20-4266 · Cited by 3
Xiao, H., Du, Y., Tan, Y., & Ren, Y. (2024) · Frontiers in Nutrition · doi:10.3389/fnut.2024.1510403 · Cited by 2
Luo, J.-C., Jin, L.-H., Zhong, Y.-S., Xu, X., Zhang, Z.-Y., Chen, J., Chen, Z.-X., Li, S., Zhang, X.-D., & Qian, J. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.114631 · Cited by 2
Ostrominski, J. W., Aroda, V. R., Braae, U. C., Kruse, C., Mandavya, K., & Buse, J. B. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01751-6 · Cited by 2
Ray, A., Sreedhara, S. K., Paik, J. M., CROMER, S. J., Bykov, K., Hahn, G., Glynn, R. J., Wexler, D. J., & Patorno, E. (2026) · Journal of General Internal Medicine · doi:10.1007/s11606-026-10170-7 · Cited by 2
Chen, S., Zhang, L., Zong, A., Gan, Z., Zhang, X., Du, F., liu, H., & Xu, T. (2026) · Nutrition Journal · doi:10.1186/s12937-026-01292-z · Cited by 2
Milluzzo, A., Quaranta, G., Barbagallo, F. D. G., Marco, M. D., Carrubba, N., Oteri, V., Sciacca, L., & Frittitta, L. (2026) · Endocrine Practice · doi:10.1016/j.eprac.2026.06.006 · Cited by 2
Glycated Albumin Guided Therapy in Newly Diagnosed Type 2 Diabetes A Randomized Controlled Trial
Ren, Q., Zhang, R., Huang, W., Yang, X., Xu, J., Li, Y., Lin, S., Duan, J., Yan, H., Fang, C., et al. (2026) · Journal of Diabetes · doi:10.1111/1753-0407.70263 · Cited by 2
The diabetic patient between sustainability and effectiveness of new treatments
Ferrara, F., Zovi, A., Langella, R., Nava, E., & Trama, U. (2023) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-023-01296-0 · Cited by 2
Trinacty, J., & Goldenberg, R. (2024) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2024.11.007 · Cited by 2
Blood glucose, antidiabetic drugs, and risk of stroke
Lee, M., & Ovbiagele, B. I. (2021) · Precision and Future Medicine · doi:10.23838/pfm.2020.00156 · Cited by 2
Krajnc, M., & Tramšek, N. A. K. (2023) · European journal of medical research · doi:10.1186/s40001-023-01081-y · Cited by 2
Sherrill, C. H., & Hwang, A. Y. (2023) · Annals of Pharmacotherapy · doi:10.1177/10600280231178886 · Cited by 2
Stroke Prevention by Antihyperglycemic Drugs in Type 2 Diabetes Mellitus
Albert, S. G., Shrestha, E., & Ahir, V. (2023) · Endocrine Practice · doi:10.1016/j.eprac.2023.12.007 · Cited by 2
Montero, A. R., Nassar, C. M., Ahmed, S., & Magee, M. F. (2024) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2023-003788 · Cited by 2
Liraglutide and semaglutide: comparative assessment of metabolic and side effects
Romantsova, T. I. (2024) · Endocrinology News Opinions Training · doi:10.33029/2304-9529-2024-13-4-72-83 · Cited by 2
Patil, S. C., Killedar, S. G., Manjappa, A. S., More, H. N., Disouza, J., Jarag, R. J., & Potdar, V. H. (2025) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2025.106800 · Cited by 2
Agareva, M. Y., Michurina, S. S., Tomilova, A., Shestakova, E., Voznesenskaya, А. А., Sineokaya, M. S., Zubkova, E., Ratner, E. I., Stafeev, I., Parfyonova, Y., et al. (2025) · BMC Endocrine Disorders · doi:10.1186/s12902-025-01999-w · Cited by 2
Kim, Y., Huh, J. H., Lee, M., Kang, E. S., Soo, B., & Lee, B. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.880164 · Cited by 2
Improving the health of adolescents: the Nordic countries can help fill the evidence gap
Klepp, K., Helleve, A., Fismen, A., & Rutter, H. (2022) · Scandinavian Journal of Public Health · doi:10.1177/14034948221124675 · Cited by 2
Sustainability and evolution of health care regarding treatments concerning type 2 diabetes mellitus
Ferrara, F., Zovi, A., Langella, R., Cavallaro, F., Nava, E., Trama, U., & Vitiello, A. (2023) · Ethics Medicine and Public Health · doi:10.1016/j.jemep.2023.100890 · Cited by 2
Awareness of Use of GLP-1 agonists in the treatment of Diabetes Mellitus in Pakistan
Baig, M. U., & Farooq, M. A. (2023) · Journal of the Pakistan Medical Association · doi:10.47391/jpma.8210 · Cited by 2
Glucagon-related advancements in diabetes therapy
Sinha, B., Ghosal, S., Mukhopadhyay, S., Hussain, A., Mohan, A. R., Schwarz, P. E. H., & Cos, X. (2023) · Journal of Diabetology · doi:10.4103/jod.jod_96_23 · Cited by 1
Liraglutide does not increase heart rate of diabetic patients during acute myocardial infarction
Li, Q., Wu, C., Sun, S., Yang, L.-C., Li, Y., Niu, Y., Zhang, L., Li, W., & Yu, Y. (2024) · Journal of Diabetes · doi:10.1111/1753-0407.13517 · Cited by 1
Sasaki, L. S., COSTA, F. G., Martins, A. B., Vieitas, M. S., Lima, A. L. S., & Monteiro, A. M. Z. A. (2024) · Cuadernos de Educación y Desarrollo · doi:10.55905/cuadv16n13-021 · Cited by 1
From viper jelly to artificial pancreas – a history of diabetes treatment
Banaszak, M., Górna, I., Przysławski, J., & Drzymała-Czyż, S. (2024) · Acta Poloniae Pharmaceutica - Drug Research · doi:10.32383/appdr/194092 · Cited by 1
GLP-1 receptor agonism in cardiovascular disease prevention
Saleh, H. (2025) · Asia-Pacific Journal of Pharmacotherapy & Toxicology · doi:10.32948/ajpt.2024.11.22 · Cited by 1
Roles of Empagliflozin in Diabetic Cardiomyopathy: A Review
Luo, H., Zhang, N., Liu, Y., Chen, P., Duan, P., Lou, X., Yu, H., Lei, Q., Zhao, G., Wang, M., et al. (2025) · Current Vascular Pharmacology · doi:10.2174/0115701611319744250116092707 · Cited by 1
Metformin as First-line Therapy: Response to Drs Trinacty and Goldenberg
Shah, B. R., BAJAJ, H. S., Butalia, S., Dasgupta, K., Eurich, D. T., Jain, R., Mansell, K. D., & Simpson, S. H. (2025) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2024.12.006 · Cited by 1
Efficacy and safety of insulin sensitisers for treating type 2 diabetes: a network meta-analysis
Huang, G., Li, Y., Shang, Y., Wang, H., Zhang, W., & Guo, H. (2025) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-025-03882-y · Cited by 1
Meng, L., Yang, L., Zhu, X., Sun, Z., Zhang, X., & Cui, W. (2025) · Scientific Reports · doi:10.1038/s41598-025-18015-9 · Cited by 1
af Geijerstam, P., Johansson, E., Fägerstam, S., Wu, J. H. Y., Ghafouri, B., Karlsson, K., Hebib, L., Kastbom, L., Wennberg, P., Hedov, E. G., et al. (2025) · BMJ Open · doi:10.1136/bmjopen-2025-110141 · Cited by 1
Darvishi, A., Daroudi, R., Dehghan, S., Heshmat, R., & Shafiee, G. (2025) · Scientific Reports · doi:10.1038/s41598-025-25456-9 · Cited by 1
Shabil, M., Kasoj, M., Sulthana, H., Ullah, A., Verma, A., Sah, R., Mehta, R., & Babaresh, W. M. (2025) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s560762 · Cited by 1
Bourron, O., & Denimal, D. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70497 · Cited by 1
Genetically Simulated GLP-1 Receptor Agonism and Cerebral Small Vessel Disease
Zangas, P., Omarov, M., & Georgakis, M. K. (2026) · Neurology Genetics · doi:10.1212/nxg.0000000000200359 · Cited by 1
Li, Z., Huang, J., Zhou, S., Luan, Y., Xie, H., Chen, Z., Xu, J., & Qian, J. (2026) · Journal of Diabetes Research · doi:10.1155/jdr/8893769 · Cited by 1
Liu, K., Zhang, J., He, H., Hu, Y.-Q., Lai, J.-H., Zhang, J., Wang, B., & Lin, X.-H. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03349-z · Cited by 1
Davies, M. J., Aroda, V. R., Bajaj, M. S., ElSayed, N. A., Giorgino, F., Green, J., Kalyani, R. R., Maruthur, N. M., Mathieu, C., Rosas, S. E., et al. (2026) · Diabetologia · doi:10.1007/s00125-026-06855-7 · Cited by 1
Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes
Kabadi, U. M. (2021) · Annals of Internal Medicine · doi:10.7326/l20-1277 · Cited by 1
Kabadi, U. M. (2021) · Journal of Diabetes Metabolic Disorders & Control · doi:10.15406/jdmdc.2021.08.00225 · Cited by 1
Ko, S. (2022) · Cardiovascular Prevention and Pharmacotherapy · doi:10.36011/cpp.2022.4.e13 · Cited by 1
Intensificación del tratamiento con insulina. Transición de pautas
Loiola, P. E., & Carbonell, A. M. P. (2022) · Diabetes práctica · doi:10.52102/diabet/pract/algoritmo/art4 · Cited by 1
Patsan, I., Tapley, A., Davoren, P. M., Fielding, A., Holliday, E. G., Ball, J., Davey, A., van Driel, M., Turner, R., Mulquiney, K. J., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0280668 · Cited by 1
Çizmecioğlu, H. A., Göktepe, M. H., & Çizmecioğlu, A. (2023) · Konuralp Tıp Dergisi · doi:10.18521/ktd.1295314 · Cited by 1
Pharmacotherapy of Obesity and Metabolic Syndrome
Duan, D., & Ahima, R. S. (2023) · Springer eBooks · doi:10.1007/978-3-319-12125-3_44-2 · Cited by 1
Bertoluci, M. C., Júnior, W. S. D. S., Valente, F., Araujo, L. R., Lyra, R., de Castro, J. J., Raposo, J. F., Miranda, P. A. C., Boguszewski, C. L., Hohl, A., et al. (2023) · Revista Portuguesa de Endocrinologia Diabetes e Metabolismo · doi:10.26497/na230038 · Cited by 1
Nayudu, G. S. S., Benny, B. M., Thomas, G., Khan, M. A., & Basutkar, R. S. (2024) · Indian Journal of Community Medicine · doi:10.4103/ijcm.ijcm_210_23 · Cited by 1
Liu, X., & Zhao, Y. (2024) · Tropical Journal of Pharmaceutical Research · doi:10.4314/tjpr.v23i2.19 · Cited by 1
Wang, J., Nirantharakumar, K., Sainsbury, C. A. R., Moore, D., Sinclair, A. J., Thomas, G. N., Hanif, W., Singh, M., Tan, L., Wang, Z., et al. (2024) · Systematic Reviews · doi:10.1186/s13643-024-02558-5 · Cited by 1
Metadata
- Authors
- Tsapas, A., Avgerinos, I., Karagiannis, T., Malandris, K., Manolopoulos, A., Andreadis, P., Liakos, A., Matthews, D. R., & Bekiari, E.
- Affiliations
- Clinical Research and Evidence-Based Medicine Unit and Diabetes Centre, Aristotle University of Thessaloniki, Thessaloniki, Greece, and Harris Manchester College, University of Oxford, Oxford, United Kingdom (A.T.)
- Aristotle University of Thessaloniki (GR)
- Churchill Hospital (GB)
- ORCID
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2020-08-18
- Volume
- 173
- Issue
- 4
- Pages
- 278-286
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W3037508799
- Cited by
- 346
- References
- 34
- Citations by year
- 2026: 31 · 2025: 62 · 2024: 75 · 2023: 67 · 2022: 51 · 2021: 50 · 2020: 10
- FWCI
- 33.56
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Annals of Internal Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- European Foundation for the Study of Diabetes (PAtient-Centred Treatment to support a holistic approach towards type 2 diabetes (PACT) Programme supported by an unrestricted educational grant from AstraZeneca)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, antidiabetic drugs, comparative effectiveness, metformin, GLP-1 receptor agonists, SGLT2 inhibitors, semaglutide, empagliflozin, liraglutide, dapagliflozin, canagliflozin, insulin, cardiovascular risk, all-cause mortality, cardiovascular mortality, stroke, heart failure hospitalization, end-stage renal disease, diabetic retinopathy, amputation, glycemic control, HbA1c, vascular outcomes, risk of bias
- MeSH terms
- Blood Glucose, Diabetes Mellitus, Type 2, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.